Skip to main content
Top
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Overexpression of CUGBP1 is associated with the progression of non-small cell lung cancer

Authors: Caihong Gao, Zhuang Yu, Shihai Liu, Hou Xin, Xiumei Li

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

The multifunctional RNA-binding protein CUGBP1 regulates multiple aspects of nuclear and cytoplasmic messenger RNA (mRNA) processing, including splicing, stabilization, and translation of mRNAs. Previous studies have shown that CUGBP1 is overexpressed in non-small-cell lung cancer (NSCLC) tissues, but the pathological functions of CUGBP1 in tumorigenesis and development are unknown. Here, we provide the first evidence demonstrating the clinicopathological significance of CUGBP1 in NSCLC. Using immunohistochemistry, the levels of CUGBP1 expression in NSCLC tissues and adjacent non-cancerous tissues were examined and determined to be associated with differentiation. Short hairpin RNA-induced downregulation of CUGBP1 promoted apoptosis and decreased proliferation in the A549 NSCLC cell line. Moreover, Western blot analysis indicated that the depletion of CUGBP1 increased the protein levels of cyclin D1, BAD, BAX, Jun D, and E-cadherin, while the cyclin B1 level decreased. Knockdown of CUGBP1 decreased β-catenin and vimentin levels and increased E-cadherin expression, suggesting that CUGBP1 may contribute significantly to epithelial to mesenchymal transition (EMT) progression. These results demonstrate the importance of CUGBP1 in the biological and pathological functions of NSCLC and indicate its potential as a therapeutic target for NSCLC.
Literature
1.
2.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMed
3.
4.
go back to reference Kang S, Koh ES, Vinod SK, Jalaludin B. Cost analysis of lung cancer management in South Western Sydney. J Med Imaging Radiat Oncol. 2012;56:235–41.CrossRefPubMed Kang S, Koh ES, Vinod SK, Jalaludin B. Cost analysis of lung cancer management in South Western Sydney. J Med Imaging Radiat Oncol. 2012;56:235–41.CrossRefPubMed
5.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
6.
go back to reference Koshelev M, Sarma S, Price RE, Wehrens XH, Cooper TA. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet. 2010;19:1066–75.CrossRefPubMedPubMedCentral Koshelev M, Sarma S, Price RE, Wehrens XH, Cooper TA. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet. 2010;19:1066–75.CrossRefPubMedPubMedCentral
7.
go back to reference Ward AJ, Rimer M, Killian JM, Dowling JJ, Cooper TA. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet. 2010;19:3614–22.CrossRefPubMedPubMedCentral Ward AJ, Rimer M, Killian JM, Dowling JJ, Cooper TA. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet. 2010;19:3614–22.CrossRefPubMedPubMedCentral
8.
go back to reference Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009;106:13915–20.CrossRefPubMedPubMedCentral Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009;106:13915–20.CrossRefPubMedPubMedCentral
10.
go back to reference Rattenbacher B, Beisang D, Wiesner DL, Jeschke JC, von Hohenberg M, et al. Analysis of CUGBP1 targets identifies GU-repeat sequences that mediate rapid mRNA decay. Mol Cell Biol. 2010;30:3970–80.CrossRefPubMedPubMedCentral Rattenbacher B, Beisang D, Wiesner DL, Jeschke JC, von Hohenberg M, et al. Analysis of CUGBP1 targets identifies GU-repeat sequences that mediate rapid mRNA decay. Mol Cell Biol. 2010;30:3970–80.CrossRefPubMedPubMedCentral
11.
go back to reference Vlasova IA, Tahoe NM, Fan D, Larsson O, Rattenbacher B, et al. Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1. Mol Cell. 2008;29:263–70.CrossRefPubMedPubMedCentral Vlasova IA, Tahoe NM, Fan D, Larsson O, Rattenbacher B, et al. Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1. Mol Cell. 2008;29:263–70.CrossRefPubMedPubMedCentral
12.
13.
go back to reference Zhang L, Lee JE, Wilusz J, Wilusz CJ. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. J Biol Chem. 2008;283:22457–63.CrossRefPubMedPubMedCentral Zhang L, Lee JE, Wilusz J, Wilusz CJ. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. J Biol Chem. 2008;283:22457–63.CrossRefPubMedPubMedCentral
14.
go back to reference Salisbury E, Sakai K, Schoser B, Huichalaf C, Schneider-Gold C, et al. Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Exp Cell Res. 2008;314:2266–78.CrossRefPubMedPubMedCentral Salisbury E, Sakai K, Schoser B, Huichalaf C, Schneider-Gold C, et al. Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Exp Cell Res. 2008;314:2266–78.CrossRefPubMedPubMedCentral
15.
go back to reference Jiao W, Zhao J, Wang M, Wang Y, Luo Y, et al. CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer. Clin Transl Oncol. 2013;15:789–95.CrossRefPubMed Jiao W, Zhao J, Wang M, Wang Y, Luo Y, et al. CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer. Clin Transl Oncol. 2013;15:789–95.CrossRefPubMed
17.
go back to reference Talwar S, Balasubramanian S, Sundaramurthy S, House R, Wilusz CJ, et al. Overexpression of RNA-binding protein CELF1 prevents apoptosis and destabilizes pro-apoptotic mRNAs in oral cancer cells. RNA Biol. 2013;10:277–86.CrossRefPubMedPubMedCentral Talwar S, Balasubramanian S, Sundaramurthy S, House R, Wilusz CJ, et al. Overexpression of RNA-binding protein CELF1 prevents apoptosis and destabilizes pro-apoptotic mRNAs in oral cancer cells. RNA Biol. 2013;10:277–86.CrossRefPubMedPubMedCentral
18.
go back to reference Zhou BP, Hung MC. Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle. 2005;4:772–6.CrossRefPubMed Zhou BP, Hung MC. Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle. 2005;4:772–6.CrossRefPubMed
19.
go back to reference Ciervide R, Dhage S, Guth A, Shapiro RL, Axelrod DM, et al. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:e159–64.CrossRefPubMed Ciervide R, Dhage S, Guth A, Shapiro RL, Axelrod DM, et al. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:e159–64.CrossRefPubMed
20.
go back to reference Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, et al. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer. 2009;125:381–7.CrossRefPubMed Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, et al. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer. 2009;125:381–7.CrossRefPubMed
21.
go back to reference Beisang D, Rattenbacher B, Louis IAV, Bohjanen PR. Regulation of CUG-binding protein 1 (CUGBP1) binding to target transcripts upon T cell activation. J Biol Chem. 2012;287:950–60.CrossRefPubMed Beisang D, Rattenbacher B, Louis IAV, Bohjanen PR. Regulation of CUG-binding protein 1 (CUGBP1) binding to target transcripts upon T cell activation. J Biol Chem. 2012;287:950–60.CrossRefPubMed
22.
go back to reference Gareau C, Fournier M, Filion C, Coudert L, Martel D, et al. p21WAF1/CIP1 upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis. PLoS One. 2011;6:e20254.CrossRefPubMedPubMedCentral Gareau C, Fournier M, Filion C, Coudert L, Martel D, et al. p21WAF1/CIP1 upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis. PLoS One. 2011;6:e20254.CrossRefPubMedPubMedCentral
23.
go back to reference Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol. 1982;95:333–9.CrossRefPubMed Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol. 1982;95:333–9.CrossRefPubMed
Metadata
Title
Overexpression of CUGBP1 is associated with the progression of non-small cell lung cancer
Authors
Caihong Gao
Zhuang Yu
Shihai Liu
Hou Xin
Xiumei Li
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3103-1

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine